Atorvastatin
Small molecule targets CYP3A4, HMGCR via inhibition
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (9) | US (FDA) | LIPITOR | — | 1998-07-10 – 2017-06-23 | fda.gov ↗ |
| Approved | US (FDA) | LIPITOR | — | 1996-12-17 | fda.gov ↗ |
Trials 593 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 010 trials | ||||||
| Phase 0 | NCT06961630 | Oct 2025 → Mar 2027 expected | myocardial infarction | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 0 | NCT06140095 | Feb 2024 → Dec 2025 | — | Region Stockholm | Unknown | No outcome recorded |
| Phase 0 | NCT05342974 | Apr 2022 → Dec 2023 | — | University of Utah | Completed | No outcome recorded |
| Phase 0 | NCT04862260 | Oct 2021 → Jan 2025 overdue | metastatic malignant neoplasm, pancreatic ductal adenocarcinoma | CHU de Quebec-Universite Laval | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04747847 | Jun 2019 → Aug 2022 | Kawasaki disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 0 | NCT05551624 | Jul 2018 → Dec 2019 | primary thrombocytopenia | Hospital Civil de Guadalajara | Completed | No outcome recorded |
| Phase 0 | NCT02767362 | Nov 2015 → Sep 2019 | endometrial cancer | UNC Lineberger Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02331095 | Jan 2015 → Oct 2017 | venous thromboembolism | Ohio State University | Terminated | No outcome recorded |
| Phase 0 | NCT01980823 | Oct 2013 → May 2018 | breast cancer | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT01550419 | Mar 2012 → Feb 2014 | ischemic stroke | Shanghai Minhang Central Hospital | Unknown | No outcome recorded |
| Phase 1110 trials | ||||||
| Phase 1 | NCT07608705 | Jun → Aug 2026 overdue | hyperlipidemia | Shandong Suncadia Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07530289 | Apr → May 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07534592 | Apr → Aug 2026 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07502001 | Apr → Dec 2026 expected | obesity disorder | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07389304 | Mar → Dec 2026 expected | — | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07378293 | Mar → Dec 2026 expected | diabetes mellitus | Shaheed Benazir Bhutto University Sheringal Dir Upper | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07265466 | Nov 2025 → Mar 2026 overdue | — | Onconic Therapeutics Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06948747 | May → Oct 2025 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07362030 | Apr → Dec 2025 overdue | obesity disorder | Guangdong Raynovent Biotech Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06615284 | Jan → May 2025 | coronary artery disorder, hyperlipidemia | Indication Bioscience LLC | Completed | No outcome recorded |
| Phase 1 | NCT06723691 | Dec 2024 → Jun 2025 | type 2 diabetes mellitus | Fujian Shengdi Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06601517 | Oct 2024 → Feb 2025 overdue | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06567327 | Aug 2024 → Mar 2025 | obesity disorder | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06469450 | Apr → Dec 2024 | — | Mikko Niemi | Unknown | No outcome recorded |
| Phase 1 | NCT06289504 | Feb → Oct 2024 | obesity disorder | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06293742 | Feb → Apr 2024 | type 2 diabetes mellitus | Eccogene | Completed | No outcome recorded |
| Phase 1 | NCT06699355 | Nov → Dec 2023 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06191991 | Nov 2023 | — | Aligos Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05839236 | May → Jun 2023 | COVID-19, post-COVID-19 disorder | Yang I. Pachankis | Unknown | No outcome recorded |
| Phase 1 | NCT05815680 | Apr → Aug 2023 | obesity disorder | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05681273 | Feb → Mar 2023 | type 2 diabetes mellitus | Chipscreen Biosciences, Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04922424 | Sep 2022 → Aug 2023 | hyperlipidemia, hypertensive disorder | Yale University | Withdrawn | No outcome recorded |
| Phase 1 | NCT05464628 | Aug 2022 | — | Gannex Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05372380 | May → Jun 2022 | hyperlipoproteinemia, hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05334108 | Apr → Aug 2022 | — | Emalex Biosciences Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05202405 | Jan → Mar 2022 | hyperlipidemia | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05093205 | Oct 2021 → Jul 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04972396 | Sep 2021 → May 2022 | metabolic dysfunction-associated steatohepatitis | Altimmune, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04388501 | Jun → Oct 2021 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT06312748 | May 2021 → Sep 2028 expected | diastolic heart failure | VA Office of Research and Development | Recruiting | No outcome recorded |
| Phase 1 | NCT04764851 | Feb → Apr 2021 | — | Emalex Biosciences Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04611932 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04608344 | Nov 2020 → Jan 2021 | rheumatoid arthritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 1 | NCT04627207 | Nov 2020 → Mar 2021 | cardiovascular disorder | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 1 | NCT04270370 | Mar 2020 → Jun 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04221321 | Jan → Mar 2020 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03929744 | Jun 2019 → Nov 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04262765 | Feb → Mar 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT04245046 | Jan → Feb 2019 | — | Midas Pharma GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03769870 | Jan → Feb 2019 | diabetes mellitus | Handok Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03709355 | Nov 2018 → Sep 2019 | HIV infectious disease | Viriom | Completed | No outcome recorded |
| Phase 1 | NCT03760848 | Nov 2018 → Feb 2019 | — | Galmed Pharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1 | NCT03560882 | Jul 2018 → Oct 2022 overdue | acute myeloid leukemia, myelodysplastic syndrome | Joaquina Baranda | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03801733 | Jun → Nov 2018 | — | Akebia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03311841 | Mar → Aug 2018 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT03382756 | Oct → Nov 2017 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03346187 | May 2017 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03461081 | May → Jul 2017 | hyperlipidemia, combined, 2 | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03031119 | Jan → Jul 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT02994745 | Dec 2016 → Feb 2017 | hyperlipidemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02749578 | Apr → May 2016 | — | Madrigal Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02685462 | Jan → Feb 2016 | — | Tobira Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02651753 | Jan → Mar 2016 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02641899 | Dec 2015 → Mar 2016 | — | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT02609711 | Nov 2015 → Mar 2016 | — | Ahn-Gook Pharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT02501200 | Aug → Dec 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02566187 | Aug → Oct 2015 | hyperlipidemia, hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02461004 | Jul → Oct 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02422030 | Mar 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02397590 | Mar → Jun 2015 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02378441 | Feb → Mar 2015 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02288338 | Nov 2014 → Feb 2015 | — | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02286544 | Oct 2014 → Dec 2015 | acute coronary syndrome, myocardial infarction | Karolinska Institutet | Completed | No outcome recorded |
| Phase 1 | NCT02243098 | Sep 2014 → Apr 2015 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT02185066 | Jul → Sep 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02364258 | Jul 2014 → Dec 2017 | hyperlipidemia | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 1 | NCT02156492 | Jun → Dec 2014 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02097589 | Jun → Sep 2014 | — | University of Florida | Completed | No outcome recorded |
| Phase 1 | NCT02579356 | May → Aug 2014 | essential hypertension | Samil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02066207 | Mar → Apr 2014 | familial hypercholesterolemia, hyperlipidemia, combined, 2 | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT02093390 | Mar → Apr 2014 | endometriosis, prostate cancer | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02069821 | Mar 2014 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02089061 | Mar → May 2014 | acute coronary syndrome | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02080455 | Jan → Mar 2014 | — | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01842256 | Apr → May 2013 | essential hypertension, hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01842230 | Apr → May 2013 | essential hypertension, hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01779687 | Mar → Jul 2013 | HIV infectious disease, hyperlipidemia | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01692717 | Feb → May 2013 | — | Azidus Brasil | Completed | No outcome recorded |
| Phase 1 | NCT01795937 | Feb → Mar 2013 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01765023 | Oct → Dec 2012 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01635946 | Aug 2012 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01689623 | Jun → Aug 2012 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01806324 | Apr → Nov 2012 | hyperlipidemia, hypertensive disorder | HanAll BioPharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01605344 | Apr 2012 → Jul 2013 | colorectal adenocarcinoma | UNC Lineberger Comprehensive Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT02295046 | Oct 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT02292069 | Sep 2011 | — | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 1 | NCT01363999 | Jun → Jul 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01250834 | Dec 2010 → Mar 2011 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01138072 | Jun → Aug 2010 | HIV infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT01115985 | Mar → Apr 2010 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 1 | NCT01299597 | Jan → Feb 2010 | sleep disorder | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00991705 | Jul → Sep 2009 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT00960323 | Feb → Mar 2009 | — | Mutual Pharmaceutical Company, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00739999 | Dec 2008 → May 2009 | familial hypercholesterolemia | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00722956 | Jul → Aug 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00681525 | Apr → Jun 2008 | — | Abbott | Completed | No outcome recorded |
| Phase 1 | NCT00637481 | Mar 2008 → Oct 2012 | ductal breast carcinoma in situ, lobular breast carcinoma in situ | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02094313 | Jan 2008 → Jan 2014 | — | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00411190 | Oct → Dec 2006 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02171039 | Jun → Aug 2006 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01518166 | May 2006 → Apr 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT00143741 | May 2005 → Dec 2010 | end stage renal failure | University of Chicago | Completed | No outcome recorded |
| Phase 1 | NCT00491751 | May 2004 → Jun 2012 | peripheral arterial disease | Boston University | Terminated | No outcome recorded |
| Phase 1 | NCT00974740 | Mar 2004 → Jan 2008 | type 1 diabetes mellitus | Profil Institute for Metabolic Research GmbH | Terminated | No outcome recorded |
| Phase 1 | NCT02245269 | Jul → Oct 2003 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT02587416 | Nov → Dec 2002 | hyperlipoproteinemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00017758 | — | HIV infectious disease, lipodystrophy | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02614352 | ? → Feb 2016 | — | Ahn-Gook Pharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT00164086 | — | plasma cell myeloma | Bayside Health | Unknown | No outcome recorded |
| Phase 1 | NCT00000941 | ? → Mar 2002 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT07630363 | May 2026 → Mar 2028 expected | clear cell renal carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06684509 | Nov 2024 → Sep 2027 expected | Hodgkins lymphoma, leukemia | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06553157 | Sep 2024 → Jul 2025 | cancer, platinum-induced ototoxicity | Minia University | Completed | No outcome recorded |
| Phase 1/2 | NCT06208384 | Jan 2024 → Jan 2025 | dry eye syndrome | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT03188978 | Nov 2018 → Dec 2019 | — | Albany Medical College | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03460808 | Mar 2018 → Jan 2020 | autoimmune thrombocytopenia | Peking University People's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03308578 | Jan 2018 → Dec 2023 | obstructive sleep apnea syndrome | Mayo Clinic | Completed | No outcome recorded |
| Phase 1/2 | NCT02380625 | Apr 2015 → Jan 2016 | Ebola hemorrhagic fever | Clinical Research Management, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01431105 | Jul 2012 → Jan 2018 | Kawasaki disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 1/2 | NCT01617538 | Jan 2012 → Mar 2013 | — | Capital Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT00663234 | Aug 2009 → Dec 2014 | HIV infectious disease, hyperlipidemia | International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Terminated | No outcome recorded |
| Phase 1/2 | NCT00519363 | Sep 2007 → Oct 2008 | systemic lupus erythematosus | The Center for Rheumatic Disease, Allergy, & Immunology | Completed | No outcome recorded |
| Phase 1/2 | NCT01785615 | Nov 2004 → Dec 2011 | metabolic syndrome X | University of Rochester | Completed | No outcome recorded |
| Phase 2108 trials | ||||||
| Phase 2 | NCT07685938 | Jul 2026 → Feb 2029 expected | breast cancer, esophageal cancer, lung cancer, mediastinal cancer +2 | UNC Lineberger Comprehensive Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07303699 | Jan 2026 → Mar 2027 expected | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07307989 | Aug 2025 → Jul 2029 expected | hyperlipidemia, ischemic stroke | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT02958852 | Jan 2025 | breast cancer | Lund University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06157099 | Sep 2024 → Mar 2028 expected | cutaneous melanoma | OHSU Knight Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04915183 | Jul 2024 → Aug 2028 expected | head and neck squamous cell carcinoma, hearing loss disorder | National Institute on Deafness and Other Communication Disorders (NIDCD) | Recruiting | No outcome recorded |
| Phase 2 | NCT06327451 | Apr 2024 → Feb 2026 overdue | IDH-wildtype glioblastoma | Tianjin Medical University General Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06241352 | Mar 2024 → Apr 2025 | malignant pancreatic neoplasm | Changhai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT05483010 | Feb 2024 → May 2027 expected | clonal hematopoiesis of indeterminate potential, myelodysplastic syndrome | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06199921 | Jan 2024 → Mar 2026 overdue | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05028829 | May 2023 → Dec 2026 expected | cirrhosis of liver, fibrotic liver disease | Raymond Chung | Recruiting | No outcome recorded |
| Phase 2 | NCT06102863 | Apr 2023 → Aug 2025 overdue | endometrial disorder | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04679376 | Jan 2023 → Dec 2026 expected | metabolic dysfunction-associated steatohepatitis | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05675787 | Jan 2023 → Aug 2025 overdue | atypical endometrial hyperplasia, endometrial carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07668076 | Nov 2022 → Oct 2024 | breast cancer, doxorubicin induced cardiomyopathy | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT05559164 | Sep 2022 → Sep 2026 expected | breast cancer, poisoning | Rutgers, The State University of New Jersey | Recruiting | No outcome recorded |
| Phase 2 | NCT02497638 | Dec 2021 | prostate cancer | University Health Network, Toronto | Withdrawn | No outcome recorded |
| Phase 2 | NCT05895123 | Nov 2021 → Mar 2023 | ST-elevation myocardial infarction | Damanhour University | Completed | No outcome recorded |
| Phase 2 | NCT04984616 | Oct 2021 → Mar 2024 | Chagas disease | Juan D. Maya | Terminated | No outcome recorded |
| Phase 2 | NCT04767984 | Sep 2021 → Dec 2025 overdue | colorectal carcinoma, ulcerative colitis | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04765137 | May 2021 → Jul 2027 expected | cognitive impairment with or without cerebellar ataxia | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 2 | NCT04824911 | Mar 2021 → Feb 2025 | stroke disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04735263 | Feb 2021 → Apr 2027 expected | age-related macular degeneration | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 2 | NCT04472637 | Nov 2020 → May 2021 | arteriosclerosis disorder | Alexandria University | Completed | No outcome recorded |
| Phase 2 | NCT04380402 | Jun 2020 → Dec 2021 | COVID-19 | Mount Auburn Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03110848 | Jun 2020 → Apr 2021 | hyperlipoproteinemia, thyrotoxic exophthalmos | University of Pisa | Completed | No outcome recorded |
| Phase 2 | NCT03830164 | Nov 2019 → Nov 2022 | erectile dysfunction, prostate adenocarcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04149483 | Nov 2019 → Feb 2021 | brain aneurysm, vasculitis | Beijing Neurosurgical Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03872388 | Sep 2019 → Oct 2023 | inflammatory breast carcinoma, triple-negative breast carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT03611010 | Aug 2018 → Feb 2020 | hyperlipidemia | Cumberland Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03186404 | May 2018 → Dec 2021 | cancer, cardiomyopathy due to anthracyclines, heart failure | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 2 | NCT03047772 | Mar → Dec 2018 | myocardial infarction | Yuejin Yang | Unknown | No outcome recorded |
| Phase 2 | NCT03358017 | Mar 2018 → Jun 2021 | triple-negative breast carcinoma | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
| Phase 2 | NCT03275376 | Dec 2017 → Dec 2020 | — | Taichung Veterans General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02967653 | Jul 2017 → Jul 2019 | nephrogenic diabetes insipidus | Lady Davis Institute | Completed | No outcome recorded |
| Phase 2 | NCT03051100 | Jan → Jun 2017 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02943590 | Jan 2017 → Sep 2022 | heart failure | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02819869 | Aug → Sep 2016 | hepatocellular carcinoma | Taipei Medical University WanFang Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02674204 | May 2016 → May 2018 | breast cancer, cardiomyopathy, poisoning | Cedars-Sinai Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03867994 | Feb 2016 → May 2017 | — | rabab ahmed mohamed | Completed | No outcome recorded |
| Phase 2 | NCT01617772 | Jan 2016 → Oct 2019 | metabolic dysfunction-associated steatohepatitis | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT02633956 | Dec 2015 → Mar 2017 | metabolic dysfunction-associated steatohepatitis | Intercept Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02278471 | Dec 2015 → Jun 2018 | hyperlipidemia, hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 2 | NCT02416427 | May 2015 → Dec 2016 | breast neoplasm | Regina Elena Cancer Institute | Unknown | No outcome recorded |
| Phase 2 | NCT02432534 | May 2015 → Feb 2017 | vitiligo | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| Phase 2 | NCT02197065 | Sep 2014 → Jul 2016 | myocardial ischemia | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 2 | NCT02245087 | Aug 2014 → Sep 2019 | coronary artery disorder | University Health Network, Toronto | Terminated | No outcome recorded |
| Phase 2 | NCT02192320 | Jul 2014 → Sep 2015 | — | Oriental Neurosurgery Evidence-Based-Study Team | Unknown | No outcome recorded |
| Phase 2 | NCT01665677 | Jan 2014 → Jul 2021 | graft versus host disease | Mehdi Hamadani | Completed | No outcome recorded |
| Phase 2 | NCT02029573 | Jan 2014 → Dec 2016 | glioblastoma | King Fahad Medical City | Completed | No outcome recorded |
| Phase 2 | NCT02024373 | Dec 2013 → Apr 2016 | — | Oriental Neurosurgery Evidence-Based-Study Team | Completed | No outcome recorded |
| Phase 2 | NCT01732718 | Sep 2013 → Jan 2018 | sickle cell disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT01929135 | May 2013 → Jan 2014 | chronic periodontitis | Universidad de los Andes, Chile | Completed | No outcome recorded |
| Phase 2 | NCT01863225 | May → Jun 2013 | coronary artery disorder, hyperlipidemia | Resverlogix Corp | Terminated | No outcome recorded |
| Phase 2 | NCT02432040 | Feb → Oct 2013 | psoriasis | Philippine Dermatological Society | Completed | No outcome recorded |
| Phase 2 | NCT01761656 | Dec 2012 → Dec 2013 | acute myocardial infarction, intermediate coronary syndrome | Central South University | Unknown | No outcome recorded |
| Phase 2 | NCT01779453 | Dec 2012 → Aug 2013 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01733953 | Nov 2012 → Nov 2015 | cardiovascular disorder, childhood acute lymphoblastic leukemia | University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01759836 | Oct 2012 → Sep 2021 | prostate cancer | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01527045 | Sep 2012 → Oct 2018 | Hodgkins lymphoma, Waldenstrom macroglobulinemia, adult acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia +9 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01821404 | Aug 2012 → May 2017 | prostate cancer | Tampere University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01645176 | May 2012 → Apr 2016 | osteoarthritis, knee | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT01525407 | May 2012 → Sep 2015 | cancer | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01491958 | Dec 2011 → Jan 2014 | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | Ohio State University Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01375075 | Jun 2011 → Mar 2012 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01351025 | Apr 2011 → May 2014 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT01288469 | Jan → Sep 2011 | hyperlipidemia | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01218204 | Sep 2010 → Jun 2011 | hyperlipidemia | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT01175148 | Jul 2010 → Dec 2014 | acute graft versus host disease | West Virginia University | Completed | No outcome recorded |
| Phase 2 | NCT01105975 | Apr 2010 → Jun 2011 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01013870 | Feb 2010 → Mar 2015 | post-traumatic stress disorder, traumatic brain injury | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 2 | NCT01059864 | Feb → Nov 2010 | rheumatoid arthritis | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00977288 | Sep 2009 → Mar 2010 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00804843 | Apr 2009 → Oct 2010 | atherosclerosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT01220973 | Feb 2009 → Nov 2014 | prostate cancer | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00979758 | Jan 2009 → Jun 2015 | myocardial infarction | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00816244 | Jan 2009 → Mar 2012 | breast cancer | Lund University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00687271 | Jun 2008 → Jan 2009 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00701883 | Aug 2007 → Aug 2008 | hyperlipidemia | Gilead Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00529191 | Jul 2007 → Jul 2011 | type 1 diabetes mellitus | Children's Hospital of Philadelphia | Completed | No outcome recorded |
| Phase 2 | NCT00504829 | Jul 2007 → Feb 2008 | hyperlipidemia | Veloxis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02114099 | Jun 2007 → Dec 2015 | Kawasaki disease, coronary aneurysm | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00437892 | May 2007 → May 2011 | hyperlipoproteinemia, venous thromboembolism | University of Insubria | Terminated | No outcome recorded |
| Phase 2 | NCT01111656 | Mar 2007 → Apr 2010 | relapsing-remitting multiple sclerosis | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT00452608 | Dec 2006 → Dec 2009 | infectious disease with sepsis | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| Phase 2 | NCT00446940 | Dec 2006 → Mar 2007 | hepatitis C virus infection | Bader, Ted, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT00603590 | Nov 2006 → Jun 2008 | heart disorder, hyperlipidemia, hypertensive disorder | Tehran University of Medical Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00367458 | Oct 2006 → Jun 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00490698 | Oct 2006 → Jan 2012 | renal cell carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00454545 | Oct 2006 → Oct 2007 | Crohn disease | Skane University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00751907 | Jun 2006 → Apr 2007 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 2 | NCT00335504 | Mar 2006 → Apr 2009 | colon carcinoma, precancerous condition, rectal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00359281 | Mar 2006 → Nov 2007 | — | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00296400 | Feb 2006 → Jun 2009 | hyperlipidemia | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00292201 | Feb 2006 → Jun 2013 | asthma | Queen's University | Terminated | No outcome recorded |
| Phase 2 | NCT00403533 | Feb → Jul 2006 | hepatitis C virus infection | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00133380 | Jul 2005 → Sep 2006 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00094172 | May 2005 → May 2009 | multiple sclerosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00942591 | May 2005 → Apr 2009 | relapsing-remitting multiple sclerosis | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 2 | NCT00185731 | Apr 2005 → Nov 2012 | leukemia, non-Hodgkin lymphoma | Dean Felsher | Completed | No outcome recorded |
| Phase 2 | NCT00134550 | Feb 2005 → Mar 2007 | diabetes mellitus, ulcer of lower limbs | Asker & Baerum Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00914017 | Jan 2005 → Dec 2010 | breast cancer | University of Vermont | Unknown | No outcome recorded |
| Phase 2 | NCT00529542 | Dec 2004 → Aug 2010 | polycystic ovary syndrome | Milton S. Hershey Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00166036 | Sep 2004 → Mar 2008 | diabetes mellitus, hyperlipoproteinemia, metabolic syndrome X | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT02591836 | Jan → Jun 2003 | hyperlipidemia | NeuroBo Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00412841 | Nov 2002 → Jan 2008 | avascular necrosis | NYU Langone Health | Terminated | No outcome recorded |
| Phase 2 | NCT00024531 | Oct 2000 → Aug 2004 | Alzheimer disease | Institute for the Study of Aging (ISOA) | Completed | No outcome recorded |
| Phase 2 | NCT00004466 | Oct 1998 → Dec 1999 | hyperlipidemia, nephrotic syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Terminated | No outcome recorded |
| Phase 2/312 trials | ||||||
| Phase 2/3 | NCT05103644 | Oct 2021 → Dec 2023 | breast cancer | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04857632 | Aug 2021 → Jun 2024 | intracerebral hemorrhage | Capital Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05792293 | Jun 2021 → Jun 2023 | doxorubicin induced cardiomyopathy | Ain Shams University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04721795 | Jan 2021 → Mar 2022 | pulmonary tuberculosis | Obafemi Awolowo University Teaching Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT04466241 | Nov 2020 → Nov 2021 | COVID-19 | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2/3 | NCT02913664 | Feb 2017 → Nov 2021 | hypertensive disorder, subjective cognitive decline | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT01442428 | Jan 2014 → Mar 2016 | HIV infectious disease, immune reconstitution inflammatory syndrome, tuberculosis | University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT02114346 | Jul 2013 → Feb 2014 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01259284 | Jan → Sep 2011 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2/3 | NCT00664859 | Oct 2007 → Feb 2009 | hyperlipidemia | Veloxis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT00432354 | Mar 2007 → Mar 2009 | systemic lupus erythematosus | Buddhist Tzu Chi General Hospital | Unknown | No outcome recorded |
| Phase 2/3 | NCT00153166 | Jan 2004 → Nov 2010 | arterial occlusion, intermittent vascular claudication | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 3116 trials | ||||||
| Phase 3 | NCT07530640 | Jun 2026 → Aug 2027 expected | Kawasaki disease, coronary artery disorder | Children's Hospital of Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT07474649 | Jun 2026 → Jun 2028 expected | coronary atherosclerosis, hyperlipidemia, combined, 2, hyperlipoproteinemia | Daiichi Sankyo | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07012629 | Nov 2025 → Sep 2031 expected | MRI defined brain infarct | Aarhus University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06930885 | Jun 2025 → May 2031 expected | atherosclerotic cardiovascular disease | Hospital do Coracao | Recruiting | No outcome recorded |
| Phase 3 | NCT06559072 | Sep 2024 → Jan 2026 overdue | acquired aneurysmal subarachnoid hemorrhage | The George Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05049603 | Jan 2024 → Dec 2025 overdue | disease of orbital part of eye adnexa | University of Pisa | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05930028 | Jul 2023 → Sep 2024 | essential hypertension, hyperlipoproteinemia | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT05796973 | Mar 2023 → Dec 2027 expected | breast cancer, metastatic prostate carcinoma, ovarian cancer, prostate adenocarcinoma +1 | Tampere University Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05657574 | Nov 2022 → Jun 2023 | hyperlipoproteinemia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
| Phase 3 | NCT05970679 | Aug 2022 → Apr 2023 | hyperlipoproteinemia | Daewon Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 4156 trials | ||||||
| Phase 4 | NCT07508254 | May → Oct 2026 expected | acute coronary syndrome, hyperlipidemia | Punjab Institute of Cardology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07462715 | May 2026 → Jun 2027 expected | — | Menzies Institute for Medical Research | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07554820 | Dec 2025 → Aug 2026 overdue | rheumatoid arthritis | Shaikh Zayed Hospital, Lahore | Recruiting | No outcome recorded |
| Phase 4 | NCT07042165 | Oct 2025 → Dec 2026 expected | functional diarrhea, malabsorption syndrome | Asger Lund, MD | Recruiting | No outcome recorded |
| Phase 4 | NCT07087379 | Oct 2025 → Oct 2027 expected | aortic valve stenosis, brain ischemia | Pan Xiangbin | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06690164 | Jun → Dec 2025 overdue | — | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 4 | NCT06856772 | Feb 2025 → Mar 2028 expected | atherosclerotic cardiovascular disease | Tor Biering-Sørensen | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06789432 | Feb → Oct 2025 overdue | hyperlipidemia | Dr. Md. Alimur Reza | Recruiting | No outcome recorded |
| Phase 4 | NCT06785727 | Feb 2025 → Dec 2028 expected | transient ischemic attack | Prof. dr. Nathalie van der Velde | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06785974 | Feb 2025 → Feb 2027 expected | atherosclerosis, melanoma | Erasmus Medical Center | Not yet recruiting | No outcome recorded |
| Show all 156 trials opens the full record — a long page | ||||||
| Phase not applicable68 trials | ||||||
| — | NCT07704918 | Dec 2026 → Dec 2027 expected | melanoma | University of Colorado, Denver | Not yet recruiting | No outcome recorded |
| — | NCT07662525 | Jun 2026 → Dec 2027 expected | autoimmune thrombocytopenic purpura | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07400757 | Feb 2026 → Dec 2029 expected | disease of orbital part of eye adnexa | Taipei Veterans General Hospital, Taiwan | Recruiting | No outcome recorded |
| — | NCT06841536 | May → Dec 2025 | hyperlipidemia | University of the Faroe Islands | Completed | No outcome recorded |
| — | NCT05251129 | Jan 2025 → Jun 2030 | vascular disorder | Montefiore Medical Center | Withdrawn | No outcome recorded |
| — | NCT07549932 | Jan 2024 → May 2025 | chronic obstructive pulmonary disease, statin toxicity | Mohamed Salah El-Sayed | Completed | No outcome recorded |
| — | NCT07088250 | May 2023 → Sep 2026 expected | intracerebral hemorrhage | The Second Hospital of Anhui Medical University | Recruiting | No outcome recorded |
| — | NCT05790499 | Mar → Dec 2023 | low density lipoprotein, variation in molecular weight of | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT05462262 | Oct 2022 → Jul 2029 expected | coronary atherosclerosis | Chinese Academy of Medical Sciences, Fuwai Hospital | Active not recruiting | No outcome recorded |
| — | NCT05076019 | Feb 2022 → Dec 2027 expected | atrial fibrillation | Odense University Hospital | Recruiting | No outcome recorded |
| — | NCT04943783 | Jul 2021 → Jan 2022 | vertebral artery dissection | Beijing Neurosurgical Institute | Unknown | No outcome recorded |
| — | NCT07128212 | Jan 2021 → Dec 2022 | MRI defined brain infarct | Suzhou Municipal Hospital of Anhui Province | Completed | No outcome recorded |
| — | NCT05368545 | May 2020 → Apr 2024 | coronary artery disorder | Aarhus University Hospital | Completed | No outcome recorded |
| — | NCT04333407 | Apr 2020 → Nov 2021 | COVID-19 | Imperial College London | Terminated | No outcome recorded |
| — | NCT04251364 | Feb 2020 → Oct 2021 | chronic mountain sickness | Centre d'Expertise sur l'Altitude EXALT | Completed | No outcome recorded |
| — | NCT04151355 | Oct 2019 → Sep 2020 | colorectal cancer | Ain Shams University | Unknown | No outcome recorded |
| — | NCT03966859 | Jun 2019 → Feb 2020 | — | University of Oxford | Completed | No outcome recorded |
| — | NCT05730634 | Jun 2019 → May 2022 | type 2 diabetes mellitus, vasculitis | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| — | NCT03625089 | Sep 2018 → Jun 2020 | psoriatic arthritis | Chinese University of Hong Kong | Withdrawn | No outcome recorded |
| — | NCT04215237 | Nov 2017 → Jun 2020 | atherosclerotic cardiovascular disease | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT03660293 | Apr 2017 → Jun 2019 | type 1 diabetes mellitus | Tanta University | Completed | No outcome recorded |
| — | NCT06094244 | Mar 2017 → Dec 2020 | intracerebral hemorrhage | Pomeranian Medical University Szczecin | Completed | No outcome recorded |
| — | NCT03018444 | Oct 2016 → Jan 2017 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT02776956 | Apr 2016 → Aug 2018 | atrial fibrillation | xieruiqin | Completed | No outcome recorded |
| — | NCT02764736 | Mar 2016 → Mar 2017 | dialysis disequilibrium syndrome | Albert Einstein Healthcare Network | Withdrawn | No outcome recorded |
| — | NCT02496962 | Jul 2015 → Jul 2016 | — | Shi Yang | Unknown | No outcome recorded |
| — | NCT02155530 | Jun 2014 → May 2016 | coronary artery disorder | Yonsei University | Completed | No outcome recorded |
| — | NCT02942602 | Apr 2014 → May 2016 | hyperlipidemia | Yonsei University | Completed | No outcome recorded |
| — | NCT01909739 | Jul 2013 → Aug 2015 | acute kidney injury | Yonsei University | Completed | No outcome recorded |
| — | NCT01974297 | Jul 2013 → Jun 2014 | hyperlipidemia, combined, 2 | Sang Hak Lee | Unknown | No outcome recorded |
| — | NCT01634906 | Jul 2012 → Mar 2013 | atherosclerosis, hyperlipidemia | Sint Franciscus Gasthuis | Completed | No outcome recorded |
| — | NCT01547455 | Apr 2012 → Jul 2013 | acute kidney injury | Peking Union Medical College | Completed | No outcome recorded |
| — | NCT01555632 | Mar 2012 → Feb 2013 | prostate carcinoma | University of Nebraska | Withdrawn | No outcome recorded |
| — | NCT01544309 | Mar 2012 → Jun 2014 | hyperlipidemia | Listen Trial Group | Completed | No outcome recorded |
| — | NCT00932048 | Aug 2011 → Jan 2012 | atherosclerosis, type 2 diabetes mellitus | Korea University | Withdrawn | No outcome recorded |
| — | NCT01857921 | Dec 2010 → Apr 2018 | coronary artery disorder | Yonsei University | Completed | No outcome recorded |
| — | NCT01186289 | Oct 2010 → Oct 2011 | cognitive disorder | Duke University | Withdrawn | No outcome recorded |
| — | NCT01259791 | Sep 2010 → Aug 2013 | statin toxicity | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT01127945 | May 2010 → Jul 2013 | heart failure | Yonsei University | Completed | No outcome recorded |
| — | NCT00965185 | Sep 2009 → Jan 2014 | HIV infectious disease, atherosclerosis | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT00791648 | Jul 2009 → Oct 2014 | acute kidney injury, delirium | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT00979940 | Nov 2008 → Jun 2014 | coronary artery disorder | Indiana University | Terminated | No outcome recorded |
| — | NCT00770679 | Jun 2008 → Jul 2012 | diabetes mellitus | Johns Hopkins University | Terminated | No outcome recorded |
| — | NCT01099176 | May 2008 → May 2009 | hyperlipidemia, prediabetes syndrome | Medical University of Silesia | Completed | No outcome recorded |
| — | NCT00675779 | Apr 2008 → Nov 2010 | endometriosis | Poznan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT00723320 | Feb 2008 → Dec 2010 | atherosclerosis | Ministry of Science and Technology of the People´s Republic of China | Unknown | No outcome recorded |
| — | NCT00609063 | Jan 2008 → Jun 2011 | muscle tissue disorder | Hartford Hospital | Completed | No outcome recorded |
| — | NCT00520585 | Aug → Nov 2007 | — | Masaryk University | Unknown | No outcome recorded |
| — | NCT00576576 | Jul 2007 → Mar 2010 | atherosclerosis | Emory University | Completed | No outcome recorded |
| — | NCT00610870 | Jul 2007 → Feb 2009 | — | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00497016 | May 2007 → Mar 2008 | essential hypertension | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00172419 | Mar 2007 → Dec 2008 | hyperlipidemia | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT01305317 | Jan 2007 → Jan 2008 | chronic kidney disease | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00728013 | Dec 2006 → Dec 2008 | acute coronary syndrome | Ministry of Science and Technology of the People´s Republic of China | Unknown | No outcome recorded |
| — | NCT00458055 | Nov 2006 → Sep 2007 | coronary atherosclerosis, hypoalphalipoproteinemia, inborn errors of metabolism | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| — | NCT00611143 | May 2006 → Apr 2007 | coronary artery disorder | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00505336 | Apr 2006 → Jul 2008 | diastolic heart failure | St Vincent's University Hospital, Ireland | Completed | No outcome recorded |
| — | NCT00818103 | Jan 2006 → Jan 2015 | multiple sclerosis | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT00585611 | Dec 2005 → Jun 2008 | diastolic heart failure | University of Wisconsin, Madison | Terminated | No outcome recorded |
| — | NCT00259662 | Nov 2005 → Aug 2007 | uterine adnexa cancer | Yale University | Completed | No outcome recorded |
| — | NCT00636766 | Sep 2005 → Dec 2007 | atherosclerosis, metabolic syndrome X, stroke disorder, type 2 diabetes mellitus | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| — | NCT00130481 | Apr 2005 → Apr 2007 | type 1 diabetes mellitus, type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| — | NCT00572312 | Feb 2005 → ? | chronic kidney disease, proteinuria | Medical University of Gdansk | Completed | No outcome recorded |
| — | NCT00120133 | Dec 2004 → Dec 2007 | osteoporosis | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| — | NCT00154024 | Mar 2003 → Oct 2006 | — | Technical University Dresden | Completed | No outcome recorded |
| — | NCT00329069 | May 2002 → Mar 2006 | coronary artery disorder, hyperlipidemia | University of Ulm | Completed | No outcome recorded |
| — | NCT00004564 | — | hyperlipidemia, thrombotic disease | National Center for Research Resources (NCRR) | Unknown | No outcome recorded |
| — | NCT00201552 | — | paroxysmal atrial fibrillation | National Taiwan University Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 418 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT06796660 Background | Sep 2025 → Dec 2027 expected | chronic kidney disease | Liu Zhanghong | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04379999 Comparator | Sep 2018 → Aug 2025 | Lynch syndrome | Fox Chase Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT03122639 Comparator | Sep 2017 → Jan 2020 | obstructive sleep apnea syndrome | Columbia University | Completed | No outcome recorded |
| Phase 0 | NCT02029118 Background | Oct 2012 → May 2015 | — | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT06239714 Background | Feb 2024 → Feb 2025 | hyperlipidemia | Suzhou Sanegene Bio Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT05946122 Comparator | May → Dec 2023 | — | Minia University | Unknown | No outcome recorded |
| Phase 1 | NCT05289063 Comparator | Oct 2022 → Feb 2027 expected | obstructive sleep apnea syndrome | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT05327595 Background | May 2022 → Apr 2024 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05583643 Comparator | Dec 2021 → Apr 2022 | periodontitis | Misr University for Science and Technology | Completed | No outcome recorded |
| Phase 1 | NCT04047940 Comparator | Nov 2019 → Feb 2020 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02714569 Background | Mar 2016 → Feb 2017 | hyperlipidemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02374047 Background | Jan → Jul 2015 | hyperlipidemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01518231 Comparator | Jan → Dec 2012 | stroke disorder | Zhejiang Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT01859455 Background | Jul 2011 → Jul 2012 | hyperlipidemia, low density lipoprotein cholesterol, mild elevation of | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT00990808 Background | Nov 2009 → Jun 2011 | hyperlipidemia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00973986 Comparator | Jun 2009 → Dec 2010 | coronary artery disorder | Liu Hua Qiao Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00703261 Comparator | Aug 2008 → Dec 2009 | atherosclerosis | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00627575 Comparator | Feb → Sep 2008 | epilepsy | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT03176498 Background | Dec 2026 → Jun 2027 | cerebral infarction | Sclnow Biotechnology Co., Ltd. | Suspended | No outcome recorded |
| Phase 1/2 | NCT07680595 Background | Mar 2026 → Sep 2027 expected | atherosclerosis | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06369571 Comparator | Oct 2024 → Jan 2027 expected | epilepsy, hyperlipidemia | Johns Hopkins University | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT04434365 Background | Jun → Nov 2019 | coronary artery disorder | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02603328 Comparator | Jul 2018 → Jul 2024 | cerebral cavernous malformation | University of Chicago | Completed | No outcome recorded |
| Phase 1/2 | NCT03318484 Background | Nov 2017 → Nov 2019 | atherosclerosis, peripheral arterial disease | First Affiliated Hospital of Harbin Medical University | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03247400 Comparator | Dec 2016 → Dec 2018 | vitiligo | Nicolaus Copernicus University | Completed | No outcome recorded |
| Phase 1/2 | NCT02503865 Comparator | Jan 2003 → Dec 2008 | metabolic syndrome X | Nazarbayev University | Completed | No outcome recorded |
| Phase 258 trials | ||||||
| Phase 2 | NCT06764966 Comparator | Sep 2025 → Mar 2027 expected | cirrhosis of liver | CAMC Health System | Recruiting | No outcome recorded |
| Phase 2 | NCT06922994 Comparator | Mar 2025 → Nov 2026 expected | arrhythmogenic right ventricular cardiomyopathy | Centro Cardiologico Monzino | Recruiting | No outcome recorded |
| Phase 2 | NCT06924684 Comparator | Dec 2024 → Jun 2025 overdue | ST-elevation myocardial infarction | Sheikh Zayed Federal Postgraduate Medical Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05826912 Comparator | Aug 2024 → Aug 2028 expected | traumatic brain injury | University of California, San Francisco | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06485336 Comparator | May 2024 → Dec 2028 expected | migraine disorder | St. Olavs Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06248671 Comparator | May 2024 → Dec 2028 expected | migraine disorder | St. Olavs Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05792540 Comparator | Jun 2023 → Nov 2024 | depressive disorder | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT07278830 Background | Jun 2023 → May 2024 | hyperlipidemia | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05870007 Comparator | May 2023 → Dec 2025 overdue | autosomal dominant polycystic kidney disease, chronic kidney disease | Taipei Medical University Shuang Ho Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT05567068 Comparator | Feb 2023 → Jun 2025 | inflammatory bowel disease | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05561062 Comparator | Dec 2022 → Nov 2024 | inflammatory bowel disease | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT05483894 Comparator | Aug 2022 → Jul 2024 | chronic hepatitis B virus infection, portal hypertension | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05250596 Background | Feb 2022 → Feb 2024 | acute coronary syndrome | Azienda USL Toscana Centro | Completed | No outcome recorded |
| Phase 2 | NCT04181749 Comparator | Nov 2020 → Jan 2024 | — | University of Leicester | Unknown | No outcome recorded |
| Phase 2 | NCT04056039 Comparator | Aug 2018 → Jun 2019 | cardiovascular disorder, rheumatoid arthritis | Hospital Central "Dr. Ignacio Morones Prieto" | Completed | No outcome recorded |
| Phase 2 | NCT02977065 Comparator | Mar → Dec 2017 | hyperlipidemia | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 2 | NCT02022293 Comparator | Jan 2017 → Dec 2023 | nasopharyngeal carcinoma, radiation-induced disorder | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Suspended | No outcome recorded |
| Phase 2 | NCT03004001 Background | Jan 2017 → Dec 2019 | nephrotic syndrome | Gloria Vega | Terminated | No outcome recorded |
| Phase 2 | NCT02791958 Comparator | Mar 2016 → Oct 2017 | hypertensive disorder | Ferrer Internacional S.A. | Unknown | No outcome recorded |
| Phase 2 | NCT02659397 Background | Dec 2015 → Jul 2016 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02608697 Background | Oct 2015 → May 2016 | hyperlipidemia | Catabasis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02370784 Comparator | Feb 2015 → Dec 2018 | scleroderma | Robyn T. Domsic, MD, MPH | Completed | No outcome recorded |
| Phase 2 | NCT02314208 Comparator | Jan 2015 → Sep 2017 | hereditary spastic paraplegia | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 2 | NCT02081638 Comparator | Apr 2014 → Oct 2019 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02072161 Background | Mar 2014 → Jan 2015 | hyperlipidemia | Esperion Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01988571 Comparator | Feb 2014 → Sep 2020 | breast cancer, lymphoma | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT01972178 Background | Nov 2013 → Jul 2014 | hyperlipidemia | Pronova BioPharma | Terminated | No outcome recorded |
| Phase 2 | NCT02056340 Comparator | Oct 2013 → Jun 2018 | influenza | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01970215 Comparator | Aug 2013 → Jul 2014 | hyperlipidemia | Xention Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01890967 Background | Jun 2013 → Apr 2014 | hyperlipoproteinemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01812707 Background | Mar 2013 → Jan 2014 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT02119520 Comparator | Feb 2013 → Feb 2014 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2 | NCT01455935 Comparator | Nov 2011 → Dec 2013 | stroke disorder | Jacobs Neurological Institute | Unknown | No outcome recorded |
| Phase 2 | NCT01526460 Comparator | Aug 2011 → Feb 2014 | platelet disorder, undefined | IRCCS San Raffaele | Completed | No outcome recorded |
| Phase 2 | NCT01342211 Background | Jul 2011 → Feb 2012 | hyperlipidemia | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01279590 Comparator | Mar → Nov 2011 | hyperlipidemia | Furiex Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 2 | NCT01288443 Background | Jan → Dec 2011 | hyperlipoproteinemia | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT01213498 Comparator | May 2010 → Jan 2012 | cardiovascular disorder | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 2 | NCT01208701 Comparator | May 2010 → Jan 2012 | cardiovascular disorder, type 2 diabetes mellitus | Erling Bjerregaard Pedersen | Completed | No outcome recorded |
| Phase 2 | NCT01332747 Comparator | May 2010 → May 2011 | hyperlipidemia | Jamia Hamdard University | Completed | No outcome recorded |
| Phase 2 | NCT01214746 Comparator | May 2010 → Jun 2011 | cardiovascular disorder | Regional Hospital Holstebro | Completed | No outcome recorded |
| Phase 2 | NCT00814255 Comparator | Dec 2008 → Jun 2013 | focal segmental glomerulosclerosis | NYU Langone Health | Completed | No outcome recorded |
| Phase 2 | NCT00570752 Comparator | Dec 2008 → Nov 2010 | vascular disorder | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00728910 Comparator | Jun 2008 → Aug 2009 | hyperlipidemia | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT00669695 Comparator | May 2008 → Feb 2013 | obstructive sleep apnea syndrome | University Hospital, Grenoble | Terminated | No outcome recorded |
| Phase 2 | NCT00690443 Comparator | May → Sep 2008 | hyperlipidemia | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00559962 Comparator | Oct 2007 → Oct 2008 | hyperlipidemia | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00463827 Comparator | Aug 2007 → Jun 2009 | asthma, chronic obstructive pulmonary disease | NHS Greater Clyde and Glasgow | Completed | No outcome recorded |
| Phase 2 | NCT00474240 Comparator | Apr 2007 → Oct 2008 | hyperlipidemia | Aegerion Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00615823 Comparator | Feb 2007 → Mar 2010 | pulmonary hypertension | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00666029 Comparator | Feb 2006 → Feb 2008 | metabolic syndrome X | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00296374 Comparator | Feb 2006 → Mar 2009 | diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00396721 Comparator | Jan 2006 → Oct 2009 | IgA glomerulonephritis | Josep m Cruzado | Completed | No outcome recorded |
| Phase 2 | NCT00279708 Comparator | Jan 2006 → Dec 2015 | pulmonary sarcoidosis | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00770575 Comparator | Jun 2005 → Oct 2006 | cardiovascular disorder | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00864643 Comparator | Sep 2004 → Feb 2005 | hyperlipidemia | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT00689442 Comparator | Jan → Nov 2004 | hyperlipidemia | Akros Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00616187 Comparator | Oct 2003 → Jun 2007 | relapsing-remitting multiple sclerosis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 2/321 trials | ||||||
| Phase 2/3 | NCT06974084 Comparator | Jul → Dec 2026 expected | long COVID-19 | HealthBio, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06975111 Comparator | Mar 2026 → Oct 2029 expected | cardiovascular disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06696820 Comparator | Nov 2024 → Mar 2026 | ischemic stroke | Xiang Luo | Completed | No outcome recorded |
| Phase 2/3 | NCT05511766 Comparator | Nov 2022 → Apr 2024 | cirrhosis of liver, hepatic encephalopathy, infectious peritonitis, varicose disease | Tanta University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05563389 Comparator | Jun 2022 → Feb 2023 | — | Tanta University | Completed | No outcome recorded |
| Phase 2/3 | NCT06403787 Comparator | May 2022 → Apr 2023 | HIV infectious disease | University of Guadalajara | Completed | No outcome recorded |
| Phase 2/3 | NCT03692754 Comparator | Nov → Dec 2021 | autoimmune thrombocytopenia, thrombocytopenic purpura | Shandong University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05565976 Background | Aug 2020 → Dec 2024 | cognitive impairment with or without cerebellar ataxia, ischemic stroke, metabolic syndrome X, vascular dementia | Jaime Daniel Mondragon | Unknown | No outcome recorded |
| Phase 2/3 | NCT04147286 Comparator | Jul 2020 → Sep 2025 overdue | pulmonary tuberculosis | University of Cape Town | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04425590 Background | Apr → Aug 2020 | ischemic stroke | Duta Wacana Christian University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03610321 Background | Sep 2019 → Sep 2021 | coronary artery disorder | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03745300 Comparator | Mar → Dec 2017 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02979704 Comparator | Sep 2016 → Jun 2017 | hyperlipidemia | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2/3 | NCT02800902 Comparator | May 2015 → Feb 2016 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02600520 Comparator | Nov 2014 → May 2015 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02455869 Comparator | Jul 2014 → Mar 2015 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02386033 Comparator | Nov 2013 → Jul 2014 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT02060032 Comparator | Feb → Nov 2013 | chronic periodontitis | Government Dental College and Research Institute, Bangalore | Completed | No outcome recorded |
| Phase 2/3 | NCT01073800 Comparator | Apr → Aug 2009 | kidney failure, myocardial infarction, stroke disorder | University of Alberta | Completed | No outcome recorded |
| Phase 2/3 | NCT00910221 Comparator | Mar 2008 → Aug 2010 | acute kidney injury | Austin Health | Completed | No outcome recorded |
| Phase 2/3 | NCT00126048 Comparator | Jul 2005 → Sep 2007 | asthma | University of Glasgow | Completed | No outcome recorded |
| Phase 3108 trials | ||||||
| Phase 3 | NCT07586540 Background | Jul 2027 → Mar 2030 expected | carotid stenosis | Middle East North Africa Stroke and Interventional Neurotherapies Organization | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07045142 Comparator | Jul 2025 → Dec 2027 expected | schizophrenia | Central South University | Recruiting | No outcome recorded |
| Phase 3 | NCT06360120 Comparator | Apr 2024 → Sep 2025 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT06358313 Comparator | Apr 2024 → May 2026 overdue | ischemic stroke | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 3 | NCT04968509 Background | Mar 2024 → Dec 2027 expected | aortic valve stenosis | Beijing Anzhen Hospital | Recruiting | No outcome recorded |
| Show all 108 trials opens the full record — a long page | ||||||
| Phase 4139 trials | ||||||
| Phase 4 | NCT07634341 Comparator | Jun 2026 → Jun 2027 expected | chronic periodontitis | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07605130 Background | May 2026 → Sep 2028 expected | cognitive disorder, intracranial arteriosclerosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07611747 Background | Apr 2026 → Apr 2031 expected | atherosclerosis, carotid artery disorder, psoriatic arthritis, spondyloarthropathy +1 | Marqués de Valdecilla Research Institute (IDIVAL) | Recruiting | No outcome recorded |
| Phase 4 | NCT06902740 Comparator | Nov 2025 → Dec 2027 expected | cerebral artery stenosis, cerebral atherosclerosis | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07180745 Comparator | Nov 2025 → Feb 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Badr University | Not yet recruiting | No outcome recorded |
| Show all 139 trials opens the full record — a long page | ||||||
| Phase not applicable66 trials | ||||||
| — | NCT07699003 Background | Aug 2026 → Aug 2029 expected | cerebral artery occlusion | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| — | NCT07626840 Comparator | Jun 2026 → Jun 2028 expected | acute coronary syndrome | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| — | NCT07524101 Comparator | May 2026 → Jan 2031 expected | atherosclerosis, chronic kidney disease, hyperlipidemia | Yonsei University | Recruiting | No outcome recorded |
| — | NCT07624604 Background | May → Oct 2026 expected | — | University of Medicine and Pharmacy at Ho Chi Minh City | Not yet recruiting | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07359105 Comparator | Mar 2026 → Dec 2029 expected | type 2 diabetes mellitus | Sin Gon Kim | Recruiting | No outcome recorded |
| — | NCT06791031 Background | Jan 2026 → Dec 2027 expected | coronary atherosclerosis | West China Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06896708 Background | Aug 2025 → Jul 2027 expected | coronary atherosclerosis | Liu yong | Recruiting | No outcome recorded |
| — | NCT06782243 Comparator | Dec 2024 → Jul 2025 | acute coronary syndrome | Khyber Medical University Peshawar | Completed | No outcome recorded |
| — | NCT06551298 Comparator | Oct 2024 → Aug 2025 overdue | hyperlipidemia | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| — | NCT06871358 Comparator | Sep → Oct 2024 | ST-elevation myocardial infarction | Universitas Sebelas Maret | Completed | No outcome recorded |
| — | NCT06096909 Background | Nov 2023 → Nov 2025 overdue | acute coronary syndrome | China National Center for Cardiovascular Diseases | Not yet recruiting | No outcome recorded |
| — | NCT07702669 Background | Oct 2023 → Aug 2025 | metabolic syndrome X | First Affiliated Hospital of Heilongjiang Chinese Medicine University | Completed | No outcome recorded |
| — | NCT07378228 Background | Jul 2023 → Jun 2024 | coronary artery disorder | Xikun Li | Completed | No outcome recorded |
| — | NCT05705804 Comparator | Jun 2023 → May 2027 expected | atherosclerotic cardiovascular disease, hyperlipidemia | Yonsei University | Recruiting | No outcome recorded |
| — | NCT06364124 Background | Jun 2023 → Jun 2024 | ST-elevation myocardial infarction | Beijing Luhe Hospital | Unknown | No outcome recorded |
| — | NCT05479097 Background | Feb → Aug 2023 | hypertensive disorder | University of Wisconsin, Madison | Completed | No outcome recorded |
| — | NCT05679102 Comparator | Dec 2022 → Jan 2023 | — | Himayat Ullah | Completed | No outcome recorded |
| — | NCT05624658 Background | Sep 2022 → May 2024 | hyperlipidemia | Samara Regional Cardiology Dispensary | Unknown | No outcome recorded |
| — | NCT05397405 Background | May 2022 → May 2026 overdue | cerebral artery stenosis | Nanjing First Hospital, Nanjing Medical University | Recruiting | No outcome recorded |
| — | NCT05398393 Background | Jan 2022 → Jun 2023 | chronic hepatitis B virus infection, lip disorder | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT04974814 Comparator | May 2021 → Oct 2022 | ST-elevation myocardial infarction | Beni-Suef University | Unknown | No outcome recorded |
| — | NCT04581759 Background | Apr 2021 → Apr 2023 | ischemic stroke | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| — | NCT04718155 Comparator | Mar 2021 → Apr 2022 | traumatic brain injury | Assiut University | Completed | No outcome recorded |
| — | NCT04744571 Background | Feb 2021 → Dec 2022 | arterial occlusion, coronary artery disorder | Beijing Anzhen Hospital | Unknown | No outcome recorded |
| — | NCT04626973 Comparator | Jan 2021 → Sep 2025 | atherosclerotic cardiovascular disease | Yonsei University | Completed | No outcome recorded |
| — | NCT04900155 Comparator | Nov 2020 → Nov 2024 | COVID-19, ST-elevation myocardial infarction | Penza State University | Unknown | No outcome recorded |
| — | NCT04666389 Comparator | Oct 2020 → Dec 2022 | acute kidney injury, cardiovascular disorder | I.M. Sechenov First Moscow State Medical University | Completed | No outcome recorded |
| — | NCT04607447 Background | Aug 2020 → Aug 2023 | — | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT04656028 Background | Jun 2020 → Jan 2025 overdue | defective apolipoprotein b-100, hypercholesterolemia, autosomal dominant, 3, hypercholesterolemia, autosomal dominant, type B, hypercholesterolemia, familial, 1 +1 | National Medical Research Center for Therapy and Preventive Medicine | Active not recruiting | No outcome recorded |
| — | NCT04101136 Comparator | Sep 2019 → Jul 2020 | cytomegalovirus infection | Dr Cipto Mangunkusumo General Hospital | Unknown | No outcome recorded |
| — | NCT03703635 Background | Oct 2018 → May 2023 | cerebral artery stenosis | Ministry of Science and Technology of the People´s Republic of China | Unknown | No outcome recorded |
| — | NCT03391830 Comparator | Jan 2018 → Jan 2020 | acute kidney injury | Mansoura University | Completed | No outcome recorded |
| — | NCT03355027 Background | Nov 2017 → Sep 2019 | atherosclerosis | Cambridge University Hospitals NHS Foundation Trust | Unknown | No outcome recorded |
| — | NCT03273972 Background | Sep 2017 → Oct 2018 | atherosclerosis | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT05306990 Comparator | Apr 2017 → Jun 2019 | type 2 diabetes mellitus | Helwan University | Completed | No outcome recorded |
| — | NCT01987310 Comparator | Dec 2015 | NAFLD1 | Sheba Medical Center | Withdrawn | No outcome recorded |
| — | NCT03127631 Comparator | Oct 2015 → Dec 2026 expected | cardiovascular disorder, prostate cancer | McMaster University | Active not recruiting | No outcome recorded |
| — | NCT02459574 Comparator | May 2015 → Sep 2018 | atrial fibrillation, heart failure | Imperial College London | Completed | No outcome recorded |
| — | NCT02219191 Comparator | Aug 2014 → Dec 2018 | rheumatoid arthritis | Chengdu PLA General Hospital | Unknown | No outcome recorded |
| — | NCT01925937 Background | Jun 2013 → Jan 2014 | congestive heart failure | Isfahan University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01974544 Background | May 2013 → Dec 2015 | type 2 diabetes mellitus | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| — | NCT01997294 Comparator | Jan 2013 → Feb 2017 | acute myocardial infarction | Zhang Qi, MD | Unknown | No outcome recorded |
| — | NCT01751295 Comparator | Dec 2012 → Aug 2014 | coronary artery disorder | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT01702987 Comparator | Oct 2012 → Oct 2013 | hyperlipidemia, myopathy, statin toxicity | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| — | NCT01780948 Comparator | Sep 2012 → Jan 2013 | — | Chulalongkorn University | Completed | No outcome recorded |
| — | NCT01665235 Background | Aug 2012 → Aug 2014 | cerebral artery stenosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT01686230 Background | Jul 2012 → Jul 2017 | intermediate coronary syndrome | Chengdu University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT02681653 Comparator | Jan 2012 → Oct 2014 | infectious disease with sepsis | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Completed | No outcome recorded |
| — | NCT01544751 Comparator | Sep 2011 → Jun 2015 | NAFLD1 | Prof Antonino Belfiore | Unknown | No outcome recorded |
| — | NCT01071993 Comparator | Mar 2010 → Jul 2013 | — | University of Oklahoma | Terminated | No outcome recorded |
| — | NCT01491256 Comparator | Feb 2010 → Nov 2011 | acute coronary syndrome | The Korean Society of Circulation | Unknown | No outcome recorded |
| — | NCT01306565 Comparator | Jan 2009 → Jun 2010 | cardiovascular disorder | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| — | NCT00756886 Comparator | Sep 2008 → May 2011 | cardiac rhythm disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT00760786 Comparator | Jul 2008 → Feb 2010 | acute coronary syndrome | Samsung Medical Center | Unknown | No outcome recorded |
| — | NCT00691314 Comparator | Jun 2008 → Sep 2010 | atherosclerosis, transient ischemic attack | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT01126684 Comparator | Jun 2008 → Dec 2009 | essential hypertension, hyperlipidemia | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| — | NCT00664846 Background | Apr 2008 → Dec 2010 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00967434 Comparator | Dec 2007 → Jun 2010 | myocardial infarction, myocardial ischemia | Ottawa Hospital Research Institute | Completed | No outcome recorded |
| — | NCT01072097 Comparator | Sep 2006 → Jan 2011 | polycystic ovary syndrome | University of Oulu | Completed | No outcome recorded |
| — | NCT00375518 Comparator | Jul 2006 → May 2014 | — | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| — | NCT00716846 Comparator | Jun 2006 → Jul 2008 | — | Hamamatsu University | Completed | No outcome recorded |
| — | NCT00491400 Comparator | Sep 2005 → Dec 2008 | diabetes mellitus, metabolic syndrome X | Boston University | Terminated | No outcome recorded |
| — | NCT00587379 Comparator | Jun 2004 → May 2008 | — | Mayo Clinic | Withdrawn | No outcome recorded |
| — | NCT00023231 Background | Feb 2001 → Aug 2004 | end stage renal failure | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT01053065 Comparator | — | carotid stenosis, hyperlipidemia | University of Padova | Completed | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-04-04 | Daiichi Sankyo | RANBAXY'S MOHALI SEZ FACILITY BEGINS EXPORT OF ATORVASTATIN TO THE US MARKET daiichisankyo.com ↗ |
| 2011-12-01 | Daiichi Sankyo | RANBAXY ANNOUNCES LAUNCH OF ATORVASTATIN, GENERIC LIPITOR(R), IN THE U.S. daiichisankyo.com ↗ |
| 2011-12-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Generic Lipitor® tevapharm.com ↗ |
| 2011-11-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Agreement with Ranbaxy Regarding Generic Lipitor® tevapharm.com ↗ |
| 2010-05-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch and Shipment of Generic Lipitor® Tablets in Canada tevapharm.com ↗ |
Evidence & citations 49 cited values
Every value below carries the sentence it was read from. 1,019 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atorvastatin | “The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment...” NCT01190007 ↗992“The purpose of this study is to determine whether administration of lapaquistat acetate co-administered with atorvastatin, rosuvastatin or simvastatin (stable statin therapy)...” NCT00249899 ↗ “Aspirin 100mg once/day during the follow-up period, Clopidogrel 75mg once/day for at least 90 days, Atorvastatin 20-80mg once/day as the situation requires and risk factors...” NCT03703635 ↗ “The research proposal focuses on evaluating the efficacy of atorvastatin in reducing cardiotoxicity caused by anthracycline chemotherapy in patients with hematologic...” NCT06684509 ↗ “Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the...” NCT01588795 ↗ “One of ARBs(Valsartan, Olmesartan, Candesartan, Telmisartan, Fimasartan, Losartan and Irbesartan) and one of statins(Rosuvastatin, Atorvastatin, Pitavastatin, Simvastatin,...” NCT04061824 ↗ “This study will be testing an approved dose of atorvastatin (40 mg) and doses of CBD in the approved range (100 mg and 200 mg, approximately 1.7 mg/kg/day and 3.3 mg/kg/day for...” NCT06615284 ↗ “Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20...” NCT00850460 ↗ “the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the...” NCT01633359 ↗ “Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin...” NCT02072161 ↗ “Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Treatment includes high-intensity statins (atorvastatin 40-80mg, rouvastatin 20-40mg), with possible addition of azetimibe, bempedoic acid, and/or PCSK9 inhibitors if target is...” NCT07611747 ↗ “A combination of a lipophilic statin (Atorvastatin, Lipitor), a NPC1L1 inhibitor (Ezetimibe, Ezetrol) and a PCSK9 inhibitor (Evolocumab, Repatha) with chemotherapy in pancreatic cancer” NCT04862260 ↗ “First line agents will be generic statin medications (atorvastatin or rosuvastatin)whichever is covered by the participant's health insurance), barring contraindication to their use.” NCT06975111 ↗ “Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor)” NCT01502943 ↗ “The current study is designed to test the long-term (12-month) safety and efficacy of LCP-AtorFen, a combination of atorvastatin and fenofibrate, in patients with dyslipidemia” NCT00664859 ↗ “The initial recommended therapy is 20mg atorvastatin/10mg rosuvastatin plus Ezetimibe or PCSK9i, and the type and dosage of drugs can be adjusted according to the situation.” NCT06896708 ↗ “In this study, the combination therapy strategy will utilize Pitavastatin 1-4 mg plus Ezetimibe 10 mg once daily or Atorvastatin 10-20 mg plus Ezetimibe 10 mg once daily.” NCT07524101 ↗ “Participants received either 10-mg ezetimibe/5-mg atorvastatin (EZE10/ATV5), 10-mg ezetimibe (EZE10), 5-mg atorvastatin (ATV5), or 10-mg atorvastatin (ATV10).” PMID 40251695 ↗ Apr 2025 “To compare the CKD-391 (Experimental product) to the dose Atorvastatin calcium and Ezetimibe combination in health male subjects is the purpose of this trial.” NCT02461004 ↗ “The moderate intensity statins used during the study are one of atorvastatin 10-20mg qd, resuvastatin 5-10mg qd, and xuezhikang 0.6g bid (statin intolerance).” NCT05976893 ↗ “The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.” NCT02347098 ↗ “The standard statin therapy of 40-80mg oral daily dose of Atorvastatin or other equivalent types of statin to lower LDL in blood for both randomized groups.” NCT01004406 ↗ “Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02107898 ↗ “Rosuvastatin 20mg or Atorvastatin 40mg orally once daily, at the maximally tolerated dose, for 24 weeks. Dose may be adjusted for intolerance or safety.” NCT07605130 ↗ “In this study, candesartan cilexetil, amlodipine, and atorvastatin was administered orally as FDCs of 16/10/40 mg in study 1 and 16/5/20 mg in study 2.” PMID 38771476 ↗ May 2024 “A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily” NCT01271985 ↗ “can be any of the following statins: rosuvastatin, atorvastatin, simvastatin, fluvastatin, pravastatin in any of the doses causing symptoms previously” NCT01259791 ↗ “The initial recommended therapy is 10-20mg atorvastatin plus Ezetimibe, and the type and dosage of drugs can be adjusted according to the situation.” NCT05462262 ↗ “OBJECTIVES: We investigated whether atorvastatin might decrease insulin sensitivity and increase ambient glycemia in hypercholesterolemic patients.” PMID 20298928 ↗ Mar 2010 “The IMT-assigned women will receive high-dose, potent statin (atorvastatin 40-80 mg/d or rosuvastatin 20-40mg) class of lipid-lowering medications.” NCT03417388 ↗ “sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d” NCT00396721 ↗ “telmisartan 40 mg/amlodipine 5 mg/rosuvastatin 10 mg (TEL/ALD/RSV) or amlodipine 5 mg/atorvastatin 10 mg (ALD/ATV) after washout/run-in period” PMID 38380420 ↗ Feb 2024 “early addition of ezetimibe (EZ) with atorvastatin (AS), prior to reaching the maximally tolerated dose of statin, in very high-risk patients.” PMID 41673582 ↗ Feb 2026 “Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).” NCT04851769 ↗ “In one group tofacitinib (5 mg twice daily) and statins (atorvastatin 20 mg daily) will be added to the treatment regimen of the patients.” NCT07554820 ↗ “The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.” NCT00529542 ↗ “The aim of this study was to compare the pharmacokinetics (PKs) of candesartan, amlodipine, and atorvastatin FDC versus separate tablets.” PMID 41970000 ↗ Mar 2026 “To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.” NCT00441597 ↗ “The polypill comprises hydrochlorothiazide 12.5 mg, aspirin 81 mg, atorvastatin 20 mg, and either enalapril 5 mg or valsartan 40 mg.” PMID 32894967 ↗ Aug 2020 “Statins (atorvastatin or rosuvastatin) at stable maximal tolerated dose of statin with or without other LMT as clinically indicated.” NCT01663402 ↗ “Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.” NCT01342211 ↗ “Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.” NCT06096909 ↗ “Vytorin (simvastatin 20mg/ezetimibe 10mg), Atozet (atorvastatin 20mg/ezetimibe 10mg), Cretrol (rosuvastatin 10mg/ezetimibe 10mg)” NCT07307989 ↗ “antiplatelet (aspirin or/and clopidogrel,100-300mg/d) and lipid-lowering (atorvastatin 20-60mg/d,rosuvastatin 10-20mg/d) drugs” NCT04581759 ↗ “LIPITOR® (atorvastatin calcium) tablets will be administered orally as a single dose of 40 mg once daily, with or without food” NCT05559164 ↗ “40mg atorvastatin combined with 100mg fenofibrate in a tablet for once daily treatment of dyslipidemia and mixed dyslipidemia” NCT00504829 ↗ “Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)” NCT00687076 ↗ “Atorvastatin Lipitor, commonly known as Atorvastatin Calcium Tablets, 20mg*7 tablets Dose group: 10 mg once a day before bed” NCT03971019 ↗ “the endothelial treatment protocol (atorvastatin(or home statin), nicorandil, l-arginine, folic acid and vitamin B complex)” NCT04813471 ↗ “Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily” NCT00603590 ↗ “Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.” NCT06796660 ↗ “Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT02289963 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01617655 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01644175 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01954394 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01507831 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.” NCT01623115 ↗ “Statins include atorvastatin , fluvastatin , lovastatin , pitavastatin , pravastatin, rosuvastatin and simvastatin.” NCT06553157 ↗ “Atorvastatin 10 mg, 20 mg, or 40 mg, or rosuvastatin 5 mg, 10 mg, or 20 mg will be administered for up to 3 years.” NCT07359105 ↗ “Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg” NCT01245608 ↗ “Atorvastatin 20 mg or Pitavastain 4 mg or Rosuvastatin 5 mg treatment initiated within 24 hours after admission” NCT02549846 ↗ “Participants in this group will receive moderate-intensity statins (Atorvastatin 20 mg, Rosuvastatin 10 mg).” NCT06782243 ↗ “All patients will be prescribed ezetimibe and statins (atorvastatin / rosuvastatin) at the maximum dosage.” NCT04656028 ↗ “a topical drop of Atorvastatin (50 microM) will be administered, one drop eight times a day in both eyes” NCT06208384 ↗ “All patients will receive moderate-intensity statin, including atorvastatin 20 mg or rosuvastatin 10 mg.” NCT06791031 ↗ “fixed dose combination of aspirin (81mg), atorvastatin (40mg), metoprolol (50 mg), and Valsartan (40 mg)” NCT03541109 ↗ “An FDC of atorvastatin/ezetimibe 5 mg/10 mg or the corresponding individual components was administered” PMID 40206873 ↗ Mar 2025 “Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.” NCT01766076 ↗ “patients received statin (atorvastatin with a dose of 20 mg daily as an add-on therapy for 6 months).” NCT07549932 ↗ “Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy” NCT01926782 ↗ “high-intensity statin treatment with atorvastatin ≥ 40 mg daily or equivalent as background therapy” NCT03570697 ↗ “conventional lipid management (atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg)” NCT05397405 ↗ “combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)” NCT02069821 ↗ “Intensive statin could choose either Atorvastatin 40mg/day or Rosuvastatin 20mg/day, for 26 weeks” NCT05585151 ↗ “Atorvastatin Decreases Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation” NCT00201552 ↗ “Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension” NCT00741078 ↗ “Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.” NCT03318484 ↗ “atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days” NCT02288338 ↗ “Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.” NCT01686230 ↗ “to either "atorvastatin 40 mg daily" or "rosuvastatin 40 mg + ezetimibe 10 mg daily" treatment.” NCT05368545 ↗ “patients in this group received standard statin treatment： Atorvastatin statins 20mg / night .” NCT01936103 ↗ “Statin treatment (atorvastatin 20 mg or rosuvastatin 10 mg, once daily, oral) for 1 month.” NCT03610321 ↗ “Here we studied the preventive effect of atorvastatin on AKI after valvular heart surgery.” PMID 27120082 ↗ Apr 2016 “Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold” NCT03231137 ↗ “All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin” NCT01634906 ↗ “Preoperative subcutaneous injection of Evolocumab (420mg)，Atorvastatin 40mg per day” NCT06364124 ↗ “Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)” NCT01972178 ↗ “After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket” NCT02600520 ↗ “medications to reduce cardiovascular risk (aspirin and atorvastatin) if indicated” NCT05479097 ↗ “Evaluate pharmacokinetic drug-drug interaction of Candesartan and Atorvastatin” NCT02609711 ↗ “* rosuvastatin: 25 µg/mL and atorvastatin: 50 µg/mL given as 2mL oral solution” NCT04764851 ↗ “i.e. atorvastatin; dosages titrated on the patient's clinical characteristics” NCT05122780 ↗ “high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily)” NCT07699003 ↗ “atorvastatin 80 mg daily will be administered to reduce blood lipid level.” NCT02913664 ↗ “adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy” NCT01127945 ↗ “Chemotherapy was administered along with 80mg of atorvastatin per day.” NCT06241352 ↗ “Medium-dose statin daily(atorvastatin 20mg qn or rosuvastatin 10mg qn)” NCT05298475 ↗ “Atorvastatin 10, 20, and 40 mg tablets at a daily dose of 10 to 80 mg” NCT03882892 ↗ “Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.” NCT02596126 ↗ “Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.” NCT01644188 ↗ “dabigatran, pitavastatin, rosuvastatin, atorvastatin, midazolam” NCT05334108 ↗ “Atorvastatin is a potent synthetic HMG-CoA reductase inhibitor” NCT02125682 ↗ “Atorvastatin 80mg, orally administered 12 hours before surgery” NCT07087379 ↗ “135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day” NCT01030328 ↗ “10 to 20 mg/day of simvastatin or 5 to 10 mg/day atorvastatin” NCT02001883 ↗ “atorvastatin 20-40mg qd with or without ezetimibe 10mg qd” NCT04968509 ↗ “Lipidlowering: "Atorvastatin" (Liprimar) - 40mg per day.” NCT01700075 ↗ “Atorvastatin 5, 10, 20, 40, and 80mg are allowed to use” NCT05361421 ↗ “statins(Atorvastatin 20mg/day or Simvastatin 20mg/day)” NCT00691314 ↗ “will be treated with atorvastatin 10-80mg once daily.” NCT01974544 ↗ “Oral atorvastatin up to 80mg uid, for study duration.” NCT02201381 ↗ “Atorvastatin Calcium Trihydrate + Choline Fenofibrate” NCT03382756 ↗ “Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd” NCT00760786 ↗ “amlodipine/atorvastatin combination (CADUET 10/20mg)” NCT03054467 ↗ “high intensity statin (eg atorvastatin 80 mg daily)” NCT06280976 ↗ “repetitive doses of atorvastatin 40 mg once daily.” NCT06140095 ↗ “while taking Atorvastatin at a dose of 80 mg / day” NCT05624658 ↗ “reload of Atorvastatin 80 mg before the procedure” NCT01228227 ↗ “at least atorvastatin 20 mg daily or equivalent” NCT02207634 ↗ “Rosuvastatin 10mg qn or atorvastatin 20mg qn” NCT06902740 ↗ “coadministration Atorvastatin and Ezetimibe” NCT02501200 ↗ “Atorvastatin loaded in PRGF fibrin scaffold” NCT03228771 ↗ “Day 1 - 21：Atorvastatin calcium 80mg/day” NCT03635749 ↗ “Lipid-lowering: atorvastatin 20 mg/day.” NCT07088523 ↗ “Atorvastatin 20 mg tablet once daily” NCT04425590 ↗ “atorvastatin 20mg per day for 7 days” NCT04857632 ↗ “Atorvastatin 40mg / Ezetimibe 10mg” NCT05372380 ↗ “atorvastatin up to 20 mg daily” NCT00127218 ↗ “Atorvastatin/Ezetimibe 40/10mg” NCT05910476 ↗ “Atorvastatin 10 mg once a day” NCT00404599 ↗ “plus Atorvastatin 20mg (oral)” NCT03273972 ↗ “Atorvastatin or equivalent” NCT03370705 ↗ “Atorvastatin calcium 10mg” NCT03228238 ↗ “Atorvastatin 20mg PO q24h” NCT05565976 ↗ “Atorvastatin (Lipitor)” NCT02422030 ↗ “10mg of Atorvastatin” NCT01099176 ↗ “atorvastatin 20 mg/d” NCT02539810 ↗ “Other: Atorvastatin” NCT06239714 ↗ “Atorvastatin 80 mg” NCT01715714 ↗ “atorvastatin” NCT03247400 ↗ “Atorvastatin” NCT03228238 ↗ “Atorvastatin” NCT00249899 ↗ “Atorvastatin” NCT04369664 ↗ “Atorvastatin” NCT01563731 ↗ “atorvastatin” NCT00359281 ↗ “Atorvastatin” NCT01702987 ↗ “Atorvastatin” NCT03770702 ↗ “atorvastatin” NCT01890967 ↗ “atorvastatin” NCT03351998 ↗ “Atorvastatin” NCT04434365 ↗ “Atorvastatin” NCT01581476 ↗ |
| Known as | AD-221C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05131997 ↗ |
| Known as | angiotensin-converting enzyme inhibitors | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00000558 ↗ |
| Known as | ATO | “atorvastatin (ATO) combined with temozolomide (TMZ)” NCT06327451 ↗ |
| Known as | Atora | “This study will evaluate the efficacy and safety of MK-0653C (Ezetimibe \[EZ\] 10 mg/Atorvastatin \[Atora\] 10mg or 20 mg) compared to EZ 10 mg, Atora 10 mg, or Atora 20 mg...” NCT02550288 ↗1“This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC)” NCT02460159 ↗ |
| Known as | Atorva | “generic formulation of atorvastatin (Atorva®)” NCT01624207 ↗ |
| Known as | Atorvaliq | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | atorvastatin (Lipitor) | “atorvastatin (Lipitor)” NCT00127218 ↗1“atorvastatin: lipitor” NCT00153166 ↗ |
| Known as | Atorvastatin (Lipitor, 40mg) | “Atorvastatin (Lipitor, 40mg)” NCT00172419 ↗ |
| Known as | Atorvastatin Ca | “Lipitor® (Atorvastatin Ca)” NCT02069821 ↗ |
| Known as | atorvastatin calcium | “To assess the effectiveness of Atorvastatin (atorvastatin calcium) on the prevention of metabolic syndrome in men undergoing or who have undergone androgen-deprivation therapy...” NCT01555632 ↗18“Standard therapy includes valsartan capsules 80 mg orally once daily, metformin hydrochloride tablets 0.5 g orally three times daily, and atorvastatin calcium tablets 10 mg...” NCT07702669 ↗ “Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor)” NCT01502943 ↗ “Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion” NCT00407537 ↗ “Lipid Control: Medications such as atorvastatin calcium tablets (20 mg qd) or fenofibrate capsules (0.2 g qd) can be used.” NCT06796660 ↗ “Atorvastatin calcium (Lipitor) will be administered at dose of 40mg orally daily” NCT01175148 ↗ “Atorvastatin calcium 10 mg tablet to be administered orally every day” NCT01964326 ↗ “one tablet of atorvastatin calcium (20mg)” NCT07362030 ↗ “Atorvastatin Calcium, 20mg/d by mouth.” NCT03176498 ↗ “Atorvastatin Calcium tablets 80mg” NCT05589454 ↗ “Atorvastatin Calcium tablets.” NCT07608705 ↗ “Drug: Atorvastatin Calcium” NCT04767984 ↗ “Drug: atorvastatin calcium” NCT00637481 ↗ “Drug: Atorvastatin calcium” NCT01050348 ↗ |
| Known as | Atorvastatin calcium (anhydrous) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin calcium component of caduet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin calcium component of liptruzet | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin calcium component of ocustatin trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin calcium hydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin calcium salt anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin calcium salt trihydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atorvastatin Calcium Tablets | “Atorvastatin Calcium Tablets, specification: 20mg / tablet.” NCT05238012 ↗1“Drug: Atorvastatin Calcium Tablets” NCT07378228 ↗ |
| Known as | Atorvastatin Calcium Trihydrate | “Study to determine the potential pharmacokinetic interaction of candesartan cilexetil, atorvastatin as atorvastatin calcium trihydrate and amlodipine as amlodipine besilate at...” NCT04245046 ↗3“Lipitor(Atorvastatin calcium trihydrate 21.70mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)” NCT02651753 ↗ “Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)” NCT03346187 ↗ “atorvastatin as atorvastatin calcium trihydrate” NCT04262765 ↗ |
| Known as | Atorvastatin mylan | “Atorvastatin mylan 40 Mg Oral Tablet” NCT04453735 ↗ |
| Known as | Atorvastatin Sodium | “Lipitor 10mg(Atorvastatin Sodium)” NCT02166593 ↗ |
| Known as | atorvastatina | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00452608 ↗ |
| Known as | ATORVASTATINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Atrovastain | “Drug: Atrovastain” NCT06684509 ↗ |
| Known as | ATV | “OBJECTIVE: To test whether intensive atorvastatin (ATV) increases the efficacy of transplantation with autologous bone marrow mononuclear cells (MNCs) in patients suffering...” PMID 32393654 ↗ May 20209“This study evaluated the effects of anacetrapib (ANA) on lipids and safety when administered as monotherapy or in combination with atorvastatin (ATV) in Japanese patients...” PMID 23958252 ↗ Jun 2013 “in combination with intensive atorvastatin (ATV) treatment for patients with anterior ST-segment elevation myocardial infarction-elevation myocardial infarction.” PMID 31829095 ↗ Dec 2019 “Therefore, we sought to identify predictors of significant hsCRP reduction after the use of rosuvastatin (RSV)/amlodipine (AML) and atorvastatin (ATV)/AML.” PMID 40429358 ↗ May 2025 “Atorvastatin (ATV) and Simvastatin (SMV) are specific competitive inhibitors of 3-hydroxy-2-methyl-glutaryl coenzyme A reductase.” NCT02060032 ↗ “After 3 months, participants from each group will be randomized to either ASA, 81 mg PO daily, or atorvastatin (ATV), 40 mg” NCT02081638 ↗ “EZE 10 mg + atorvastatin 10 mg (EZE + ATV; n = 72) or placebo/atorvastatin 10 mg (ATV; n = 76).” PMID 17407633 ↗ Apr 2007 “Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold” NCT03231137 ↗ “After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket” NCT02600520 ↗ “Atorvastatin (ATV)” NCT02386033 ↗ |
| Known as | Calcium channel blockers | “Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed” NCT02132767 ↗ |
| Known as | CARDYL | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | CI-981 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Dronaderone | “Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.” NCT02459574 ↗ |
| Known as | Lipilou | “Lipilou®(generic atorvastatin drug) 20 mg” NCT04511000 ↗1“Atorvastatin (Lipilou)” NCT01029522 ↗ |
| Known as | Lipinon | “Atorvastatin (Lipinon)” NCT01285544 ↗ |
| Known as | Lipitor | “The purpose of the study is to investigate the effects of atorvastatin (Lipitor) and rosuvastatin (Crestor), United States Food and Drug Administration (FDA) approved drugs...” NCT00115830 ↗48“This study is designed to determine if the use of atorvastatin (Lipitor), a member of the HMG coA reductase inhibitor class of drugs referred to as statins, will reduce...” NCT00259662 ↗ “The purpose of this study is to test the effectiveness of the study drug, AEGR-733 alone and in combination with the medication, atorvastatin (Lipitor), on cholesterol in...” NCT00474240 ↗ “The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate...” NCT00296400 ↗ “This ongoing randomized trial compares one-year of atorvastatin (Lipitor™) or placebo for lowering mammography-defined breast density and other surrogate markers associated...” NCT00914017 ↗ “This study will compare atorvastatin (Lipitor) with a placebo (inactive pill) to see if this drug reduces heart rhythm abnormalities (arrhythmias) or lung inflammation after...” NCT00375518 ↗ “A combination of a lipophilic statin (Atorvastatin, Lipitor), a NPC1L1 inhibitor (Ezetimibe, Ezetrol) and a PCSK9 inhibitor (Evolocumab, Repatha) with chemotherapy in pancreatic cancer” NCT04862260 ↗ “Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor)” NCT01502943 ↗ “This study uses the cholesterol lowering drug atorvastatin, also known as lipitor, to show reduction of avascular necrosis in steroid treated lupus patients.” NCT00412841 ↗ “Name of Drugs: Niaspan (niacin extended-release tablets), Lipitor® (atorvastatin), Zocor® (simvastatin), Zetia™ (ezetimibe), and Crestor® (rosuvastatin)” NCT00079638 ↗ “The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year” NCT00296374 ↗ “The purpose of this study is to test how different doses of a statin, Lipitor, affect muscle health and function, and cardiovascular fitness.” NCT03351998 ↗ “The purpose of this study is to determine the efficacy of Lipitor (Atorvastatin) for the treatment of PCOS with elevated LDL cholesterol.” NCT00529542 ↗ “pravastatin (Pravachol ®) and atorvastatin (Lipitor®), are approved for use in people with a high cholesterol level or heart disease.” NCT00166036 ↗ “The experimental group take Lotidon 500mg/ tablet per day and Lipitor 10mg/ tablet per day for two years or until of a recurrence.” NCT02819869 ↗ “atorvastatin (Lipitor) reduces the occurence of abnormal heart rhythm (atrial arrhythmia) following non cardiac thoracic surgery.” NCT00756886 ↗ “Intervention is be atorvastatin, Lipitor® (40mg) 2 tablets daily (as adjuvant to HAART) for 12 weeks.” NCT01766076 ↗ “Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)” NCT03346187 ↗ “Lipitor (brand name for Atorvastatin), Crestor (brand name for Rosuvastatin)” NCT06782243 ↗ “Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]” NCT01043380 ↗ “A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks” NCT02791958 ↗ “Oral atorvastatin (Lipitor) therapy (10mg/day) for seven days.” NCT05331053 ↗ “standard-care lipid-lowering therapy: Zocor or Lipitor” NCT01567826 ↗ “Atorvastatin (Lipitor) and Metformin (Glucophage SR)” NCT02378441 ↗ “branded formulation of atorvastatin (Lipitor®)” NCT01624207 ↗ “3. Atorvastatin Calcium Tablets (Lipitor)” NCT07630363 ↗ “atorvastatin [Lipitor] 20, 40, or 80 mg” PMID 20136164 ↗ 2010 “Lipitor 10mg(Atorvastatin Sodium)” NCT02166593 ↗ “Atorvastatin (generic Lipitor)” NCT01600170 ↗ “1. Lipitor 80 mg PO daily or” NCT01455935 ↗ “Lipitor® (Atorvastatin Ca)” NCT02069821 ↗ “Atorvastatin (Lipitor ®)” NCT04882293 ↗ “Atorvastatin (Lipitor)” NCT01285544 ↗ “Atorvastatin (Lipitor)” NCT00442325 ↗ “Atorvastatin (Lipitor)” NCT07400757 ↗ “Atorvastatin (Lipitor)” NCT00442845 ↗ “Atorvastatin (Lipitor)” NCT00143741 ↗ “Atorvastatin (Lipitor)” NCT02422030 ↗ “Atorvastatin (Lipitor)” NCT00120055 ↗ “atorvastatin (Lipitor)” NCT00610545 ↗ “atorvastatin, Lipitor” NCT00408382 ↗ “Lipitor” NCT00532311 ↗ |
| Known as | Lipitor (Pfizer) | “Lipitor (Pfizer)” NCT01491256 ↗ |
| Known as | Lipitor (R) (Atorvastatin) | “Lipitor (R) (Atorvastatin)” NCT00194402 ↗ |
| Known as | Lipitor 10mg(Atorvastatin Sodium) | “Lipitor 10mg(Atorvastatin Sodium)” NCT02166593 ↗ |
| Known as | Liprimar | “Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin...” NCT02503865 ↗1“Lipidlowering: "Atorvastatin" (Liprimar) - 40mg per day.” NCT01700075 ↗ |
| Known as | Loading Atorvastatin 80 mg | “Loading Atorvastatin 80 mg” NCT06871358 ↗ |
| Known as | NSC-758617 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | PREVENCOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Sortis | “atorvastatin (Sortis) 40 mg” NCT00572312 ↗ |
| Known as | Tahor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02314208 ↗ |
| Known as | Torvast | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | Totalip | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Known as | ZARATOR | ChEMBL registry synonym — accepted as the source's own label CHEMBL1487 ↗ |
| Action | Inhibit | “the addition of the angiotensin-converting enzyme (ACE) inhibitor trandolapril is compared to standard therapy” NCT00000558 ↗ |
| Modality | Small molecule | “statin treatment” NCT00172419 ↗ |
| Route | Oral | “Oral tablet taken daily” NCT00023231 ↗ |
| Target | HMGCR | “Their mechanism of action entails competitive inhibition of HMG-CoA reductase.” PMID 23629822 ↗ Apr 2013 |